Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | AR | P10275 | 14/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950192 | 0.81 | HRH3 (0.43) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8026243 | 0.79 | ALDH1A1 (0.44) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL5631103 | 0.78 | AR (0.45) | ARNPC1RAB9AMAPTKMT2A | |
| SCHEMBL6884198 | 0.76 | ALDH1A1 (0.44) | LMNANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10845545 | 0.76 | ADRB2 (0.38) | SMN1; SMN2KMT2A | |
| SCHEMBL7903992 | 0.76 | MET (0.40) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11518278 | 0.74 | KDM4E (0.41) | LMNASMN1; SMN2MAPTKMT2A | |
| SCHEMBL17266277 | 0.71 | AR (0.61) | LMNAARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26684845 | 0.69 | HRH3 (0.51) | NPC1RAB9ASMN1; SMN2MAPK1KMT2A | |
| SCHEMBL7187027 | 0.69 | MAPT (0.56) | LMNAARNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554938-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024015497-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | LMNA 2879/4885AR 2232/4885NPC1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.